These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22926735)

  • 21. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
    Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
    J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
    Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
    Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
    Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
    Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
    Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics.
    Wester HJ; Schottelius M; Scheidhauer K; Reubi JC; Wolf I; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2002 Jan; 29(1):28-38. PubMed ID: 11807604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of Novel
    Poret B; Desrues L; Bonin MA; Pédard M; Dubois M; Leduc R; Modzelewski R; Decazes P; Morin F; Vera P; Castel H; Bohn P; Gandolfo P
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
    Cescato R; Waser B; Fani M; Reubi JC
    J Nucl Med; 2011 Dec; 52(12):1886-90. PubMed ID: 22068898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.
    Feijtel D; Doeswijk GN; Verkaik NS; Haeck JC; Chicco D; Angotti C; Konijnenberg MW; de Jong M; Nonnekens J
    Theranostics; 2021; 11(2):491-505. PubMed ID: 33391488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
    Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
    Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
    Stolz B; Weckbecker G; Smith-Jones PM; Albert R; Raulf F; Bruns C
    Eur J Nucl Med; 1998 Jul; 25(7):668-74. PubMed ID: 9662587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
    Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
    PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First clinical evidence that imaging with somatostatin receptor antagonists is feasible.
    Wild D; Fani M; Behe M; Brink I; Rivier JE; Reubi JC; Maecke HR; Weber WA
    J Nucl Med; 2011 Sep; 52(9):1412-7. PubMed ID: 21852357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
    Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.